SGLT2 inhibitors and the cardiorenal continuum: a paradigm shift in the treatment of patients with T2D

Abstract

Type 2 diabetes mellitus (T2D) represents a sig- nificant public health problem, with a dramat- ically increasing prevalence. T2D is considered a progressive disease that develops macro- and microvascular complications such as cardiovas- cular disease (CVD), heart failure (HF), and chronic kidney disease (CKD), which are closely interconnected and constitute the main causes of morbidity and mortality in these patients. Over time, finding new pharmacological approaches to protect against these cardiorenal events (the ‘‘cardiorenal continuum’’) has become the fundamental objective of research aimed at these patients.